T1	intervention 64 87	axitinib plus docetaxel
T2	control 95 117	docetaxel plus placebo
T3	outcome-Measure 540 565	time to progression (TTP)
T4	total-participants 575 578	168
T5	intervention-participants 603 606	112
T6	control-participants 646 648	56
T7	eligibility 311 325	Women with MBC
T8	outcome 661 671	Median TTP
T9	iv-cont-median 743 746	8.1
T10	cv-cont-median 749 759	7.1 months
T14	iv-cont-median 983 986	9.2
T13	outcome 898 908	median TTP
T15	cv-cont-median 989 999	7.0 months
T16	outcome 1044 1067	Objective response rate
T17	iv-bin-percent 1103 1108	41.1%
T18	cv-bin-percent 1111 1116	23.6%
T19	outcome 1145 1191	grades 3 to 4 treatment-related adverse events
T20	outcome 1223 1231	diarrhea
T21	iv-bin-percent 1233 1238	10.8%
T22	cv-bin-percent 1239 1241	0%
T23	outcome 1244 1251	fatigue
T24	iv-bin-percent 1253 1258	10.8%
T25	cv-bin-percent 1259 1263	5.4%
T26	outcome 1266 1276	stomatitis
T27	iv-bin-percent 1278 1283	12.6%
T28	cv-bin-percent 1284 1288	1.8%
T29	outcome 1291 1300	mucositis
T30	iv-bin-percent 1302 1306	9.0%
T31	cv-bin-percent 1307 1309	0%
T32	outcome 1312 1320	asthenia
T33	iv-bin-percent 1322 1326	7.2%
T34	cv-bin-percent 1327 1329	0%
T35	outcome 1336 1348	hypertension
T36	iv-bin-percent 1350 1354	4.5%
T37	cv-bin-percent 1355 1357	0%
T38	outcome 1410 1439	serious thromboembolic events
T39	iv-bin-abs 1360 1365	Three
T40	iv-bin-abs 1441 1444	one
T41	outcome 1445 1450	death
T42	outcome 1453 1472	Febrile neutropenia
T43	iv-bin-percent 1515 1520	15.3%
T44	cv-bin-percent 1523 1527	7.1%
T11	outcome 1595 1603	toxicity
